InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer
InspireMD (Nasdaq: NSPR) appointed Peter A. Soukas, M.D. as Chief Medical Officer effective Nov 3, 2025 to advance clinical and medical strategy around its CGuard Prime carotid stent system.
Dr. Soukas will help support the planned U.S. launch, maintain his clinical practice, and bring academic and trial experience as Director of Vascular Medicine at The Miriam Hospital and Associate Professor at Brown University.
InspireMD (Nasdaq: NSPR) ha nominato Peter A. Soukas, M.D. come Chief Medical Officer, efficace dal 3 novembre 2025, per avanzare la strategia clinica e medica legata al sistema di stent carotideo CGuard Prime.
Il Dr. Soukas supporterà il previsto lancio negli Stati Uniti, manterrà la sua pratica clinica e porterà esperienza accademica e in studi clinici come Direttore della medicina vascolare al The Miriam Hospital e Professore associato alla Brown University.
InspireMD (Nasdaq: NSPR) nombró a Peter A. Soukas, M.D. como Director Médico (Chief Medical Officer), con efecto a partir del 3 de noviembre de 2025, para impulsar la estrategia clínica y médica en torno al sistema de stents carotide CGuard Prime.
El Dr. Soukas ayudará a apoyar el previsto lanzamiento en Estados Unidos, mantendrá su práctica clínica y aportará experiencia académica y de ensayos como Director de Medicina Vascular en The Miriam Hospital y Profesor Asociado en la Universidad de Brown.
InspireMD (나스닥: NSPR)가 Peter A. Soukas, M.D.를 2025년 11월 3일부로 최고의료책임자(CMO)로 임명하여 CGuard Prime 경동맥 스텐트 시스템을 중심으로 임상 및 의료 전략을 강화합니다.
소우카스 박사는 미국 출시 계획을 지원하고 자신의 임상 진료를 지속하며 The Miriam Hospital의 혈관의학 책임자 겸 Brown University의 부교수로서 학문 및 임상시험 경험을 전하게 됩니다.
InspireMD (Nasdaq : NSPR) a nommé Peter A. Soukas, M.D. comme Directeur Médical (Chief Medical Officer) à compter du 3 novembre 2025, afin de faire progresser la stratégie clinique et médicale autour du système stent carotidien CGuard Prime.
Le Dr Soukas contribuera au lancement prévu aux États-Unis, poursuivra son activité clinique et apportera son expérience académique et d’essais en tant que Directeur de la Médecine Vasculaire à The Miriam Hospital et Professeur associé à Brown University.
InspireMD (Nasdaq: NSPR) hat Peter A. Soukas, M.D. zum Chief Medical Officer ab dem 3. November 2025 ernannt, um die klinische und medizinische Strategie rund um das CGuard Prime Carotid-Stent-System voranzutreiben.
Dr. Soukas wird den geplanten US-Start unterstützen, seine klinische Praxis fortführen und akademische sowie Studienerfahrung als Direktor der Gefäßmedizin am The Miriam Hospital und als außerordentlicher Professor an der Brown University einbringen.
InspireMD (ناسداك: NSPR) عينت الدكتور Peter A. Soukas كـ رئيس طبي، اعتباراً من 3 نوفمبر 2025، ليساهم في تعزيز الاستراتيجية السريرية والطبية حول نظام دعامات الشريان السباتي CGuard Prime.
سيساعد الدكتور Soukas في دعم الإطلاق المخطط في الولايات المتحدة، وسيواصل ممارسته السريرية، وسيجلب خبرة أكاديمية وتجارباً في التجارب كمدير الطب الأوعوي في مستشفى مريم وأستاذ مساعد في جامعة براون.
- Experienced clinical leader appointed CMO
- Supports U.S. launch of CGuard Prime
- Director of Vascular Medicine at The Miriam Hospital
- Associate Professor at Brown University
- Site PI on 24+ carotid trials
- Site PI on 150+ endovascular trials
- None.
Insights
Appointment strengthens clinical leadership ahead of the stated U.S. launch for CGuard Prime.
Bringing in Peter A. Soukas, M.D. centralizes clinical oversight and credibility for the company as it works to "launch CGuard Prime into the U.S. market." His role combines clinical stewardship with investigator experience, given his history as site principal investigator on more than 24 carotid-stenting trials and over 150 endovascular trials, and his academic and fellowship leadership positions.
The success of this hire depends on execution of clinical strategy and medical affairs activities that the company assigns to him; the announcement notes he will both lead clinical and medical topics and maintain an active clinical practice, which supports ongoing key-opinion-leader relationships and trial involvement. Watch for updates on U.S. launch milestones, clinical program enrollments, and any trial or regulatory announcements; the company made this appointment public on
MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention.
“We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company,” said Marvin Slosman, Chief Executive Officer of InspireMD. “His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insights as we launch CGuard Prime into the U.S. market. Dr. Soukas has been a strong supporter of our work advancing our next generation CGuard Prime stent platform to transform patient care through best-in-class clinical outcomes. This transformational time for carotid intervention requires us to build a team to lead the field, and Dr. Soukas will be a tremendous contributor to our work ahead.”
Dr. Soukas brings significant experience and credentials in the field of vascular intervention to InspireMD. He serves as the Director of Vascular Medicine and the Peripheral Vascular Interventional Laboratory at The Miriam Hospital and is an Associate Professor of Medicine at The Warren Alpert Medical School of Brown University, where he also directs the Vascular and Endovascular Medicine Fellowship Program, which he founded. He is a Fellow of the American College of Cardiology, the Society of Vascular Medicine, the Society of Coronary Angiography and Interventions, and the American College of Physicians. In addition to his role at InspireMD, Dr. Soukas will be maintaining his clinical practice.
Dr. Soukas’ clinical expertise and leadership in the interventional community speaks volumes for his passion and commitment to improving patient outcomes and advancing technology and innovation. He has served as the site principal investigator on more than 24 trials in carotid stenting, the site principal investigator on more than 150 endovascular trials, is a highly sought-after speaker having delivered over 300 invited lectures, and is a prolific researcher, publishing dozens of peer-reviewed papers with deep relationships among other key opinion leaders who shape the field. He is board certified in cardiovascular disease, interventional cardiology, vascular medicine, and endovascular medicine, and is certified in noninvasive vascular lab interpretation.
“I'm honored to join InspireMD as Chief Medical Officer. As a physician, I've witnessed firsthand the devastating impact of stroke and the transformative difference that innovations like CGuard Prime can make for patients,” said Dr. Soukas. “Physicians depend on the partnership with industry to advance new innovation and the team at InspireMD is an incredible example of how this ecosystem works well. My commitment is to guide the company with oversight of clinical and medical topics that build on success to date while establishing greater awareness of this breakthrough stent platform. I'm excited to join this team while continuing to collaborate with our clinical partners to advance patient care.”
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contacts:
Webb Campbell
Gilmartin Group LLC
webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
Who did InspireMD appoint as Chief Medical Officer on Nov 3, 2025 (NSPR)?
What role will Dr. Peter Soukas play in InspireMD's U.S. launch of CGuard Prime (NSPR)?
Will Dr. Soukas continue clinical practice after joining InspireMD (NSPR)?
What clinical trial experience does InspireMD's new CMO have (NSPR)?
What academic and certification credentials does Dr. Soukas hold noted by InspireMD (NSPR)?
